It had to be you: Why Roche Was the Lone Suitor for Foundation

Steve Dickman

The buzz from day one of the J.P. Morgan Healthcare Conference in San Francisco earlier this week was the announcement on Sunday night by Roche that it (Read more...)

Rethinking Venture Philanthropy After the Kalydeco Windfall

Peter Kolchinsky

The Cystic Fibrosis (CF) Foundation’s big win in venture philanthropy can fuel constructive competition among companies developing innovative CF drugs, benefiting both patients and the healthcare system by (Read more...)

What Seattle Needs (Part 2): Dealing With Amgen’s Upcoming Departure

Stewart Lyman

Reality bites: Amgen’s (NASDAQ: AMGN) decision to leave Washington state is a serious blow to our local bioscience ecosystem. Those who think that all of those people ...